Biovica International AB

BIOVIC B

SE0008613731

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
2.365 ^SEK	+3.05%		-4.64%	-8.33%

Jun. 28	Biovica to Provide Biomarker Testing for US Biopharmaceutical Company	MT
Jun. 28	Biovica International Signs New Agreement Supporting Pharma Development	CI

Biovica Elects Lars Holmqvis as Chairman

March 20, 2019 at 12:00 pm EDT

Biovica announced Lars Holmqvist was elected Chairman of the Board until the end of the next Annual General Meeting.

Latest news about Biovica International AB

Biovica to Provide Biomarker Testing for US Biopharmaceutical Company	Jun. 28	MT
Biovica International Signs New Agreement Supporting Pharma Development	Jun. 28	CI
Transcript : Biovica International AB, Q4 2024 Earnings Call, Jun 18, 2024	Jun. 18
Biovica International AB Reports Earnings Results for the Full Year Ended April 30, 2024	Jun. 18	CI
Biovica International AB Announces Divitum® Tka Results to Be Presented At Asco the Cancer Conference	May. 30	CI
Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024.	Apr. 12	CI
Biovica International AB Announces Divitum® Tka in Observational Trial	Apr. 12	CI
Biovica International AB Announces Appointments to the Nomination Committee	Apr. 11	CI
Transcript : Biovica International AB, Q3 2024 Earnings Call, Mar 14, 2024	Mar. 14
Biovica International AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 14	CI
Biovica Announces Interventional DiviTum TKa Trial Launches at Washington University	Mar. 13	CI
Biovica International Signs SEK 1.2 Million Master Service Agreement	Mar. 12	CI
Biovica Signs Master Service Agreement for Tka Testing with Leading Pharma Company	Mar. 07	CI
Biovica Partners with Palex Group to Launch Breast Cancer Treatment Response Kits; Stock Surges	Jan. 19	MT
Biovica International Signs Agreement with Palex Group	Jan. 19	CI
Biovica Receives License for Maryland State	Dec. 01	CI
Transcript : Biovica International AB, Q2 2024 Earnings Call, Nov 28, 2023	Nov. 28
Biovica International AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Nov. 28	CI
Biovica Receives Final Pricing Decision for DiviTum TKa Test by Medicare	Nov. 21	CI
Biovica Signs Commercial Partner Agreement for the Divitum(R) Tka Assay in the Nordics with Axlab	Nov. 13	CI
Biovica International AB Signs Agreement for DivTum(R) TKa with World Re-Known Cancer Clinic	23-10-12	CI
Biovica Signs Second Agreement with US Healthcare Provider	23-09-25	CI
Biovica Signs US Agreement with Leading Healthcare Provider in Arizona	23-09-19	CI
Transcript : Biovica International AB, Q1 2024 Earnings Call, Sep 06, 2023	23-09-06
Biovica International AB Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-06	CI

Chart Biovica International AB

Duration

Period

More charts

Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

Sector

Biotechnology & Medical Research

Calendar

2024-07-15 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Biovica International AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.365 SEK

Average target price

7.9 SEK

Spread / Average Target

+234.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
BIOVICA INTERNATIONAL AB	-8.33%	18.88M
EXACT SCIENCES CORPORATION	-37.33%	8.55B
GUARDANT HEALTH, INC.	+14.86%	3.8B
IOVANCE BIOTHERAPEUTICS, INC.	+7.38%	2.44B
BGI GENOMICS CO., LTD.	-25.96%	1.87B
VERACYTE, INC.	-17.30%	1.74B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+36.49%	1.19B
CAREDX, INC	+32.58%	830M
SEEGENE, INC.	-7.64%	711M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-18.37%	589M

Bio Diagnostics & Testing

Biovica International AB

Equities

BIOVIC B

SE0008613731

Biotechnology & Medical Research

Biovica Elects Lars Holmqvis as Chairman

Latest news about Biovica International AB

Chart Biovica International AB

Company Profile

Income Statement Evolution

Ratings for Biovica International AB

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Diagnostics & Testing